Veeranki, S. Phani
Xiao, Zhimin
Levorsen, Andrée http://orcid.org/0000-0001-5038-029X
Sinha, Meenal
Shah, Bimal R.
Article History
Accepted: 13 November 2020
First Online: 14 December 2020
Declarations
:
: This study was funded by Sanofi US Services, Inc.
: S.P. Veeranki was an employee of Premier Applied Sciences, Premier Inc. at the time of the study. M. Sinha is an employee of Premier Applied Sciences, Premier, Inc. Premier Applied Sciences received funding from Sanofi US Services, Inc. to conduct this study. B. Shah is employed by and holds equity from Livongo Health and also serves as a consultant for Premier Inc., Janssen, and Medtronic. Z. Xiao was an employee of Sanofi at the time of the study and is a stockholder. A. Levorsen is an employee of and stockholder in Sanofi.
: The PHD is considered exempt from Institutional Review Board oversight as dictated by Title 45 Code of Federal Regulations, Part 46 of the United States, specifically 45 CFR 46.101(b)(4). In accordance with the HIPAA Privacy Rule, disclosed data from the PHD are considered de-identified per 45 CFR 164.506(d)(2)(ii)(B) through the “Expert Determination” method.
: Not applicable.
: Data from the PHD are proprietary and cannot be shared externally.
: Not applicable.
: S.P. Veeranki, Z. Xiao, and A. Levorsen were responsible for design of the study. S.P. Veeranki and M. Sinha had full access to all the data in the study and take responsibility for the integrity of the data and accuracy of the data analysis. S.P. Veeranki interpreted the study findings with assistance from Z. Xiao and B. Shah and drafted the first draft of the manuscript. All authors were responsible for critical revision of the manuscript, for important intellectual content, and provided approval of the final draft.